Deletion of 3p12-22 is frequent in multiple cancer types, indicating the presence of critical tumor-suppressor genes (TSGs) at this region. We studied a novel candidate TSG, CMTM7, located at the 3p22.3 CMTM-gene cluster, for its tumor-suppressive functions and related mechanisms. The three CMTM genes, CMTM6, 7 and 8, are broadly expressed in human normal adult tissues and normal epithelial cell lines. Only CMTM7 is frequently silenced or downregulated in esophageal and nasopharyngeal cell lines, but uncommon in other carcinoma cell lines. Immunostaining of tissue microarrays for CMTM7 protein showed its downregulation or absence in esophageal, gastric, pancreatic, liver, lung and cervix tumor tissues. Promoter CpG methylation and loss of heterozygosity were both found contributing to CMTM7 downregulation. Ectopic expression of CMTM7 in carcinoma cells inhibits cell proliferation, motility and tumor formation in nude mice, but not in immortalized normal cells, suggesting a tumor inhibitory role of CMTM7. The tumor-suppressive function of CMTM7 is associated with its role in G1/S cell cycle arrest, through upregulating p27 and downregulating cyclin-dependent kinase 2 (CDK2) and 6 (CDK6). Moreover, CMTM7 could promote epidermal growth factor receptor (EGFR) internalization, and further suppress AKT signaling pathway. Thus, our findings suggest that CMTM7 is a novel 3p22 tumor suppressor regulating G1/S transition and EGFR/AKT signaling during tumor pathogenesis.
INTRODUCTION
Chemokine-like factor 1 (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is a novel family of proteins linking chemokines and the transmembrane-4 superfamily. 1, 2 Human CMTM family consists of nine members, CKLF and CMTM1-8, having important roles in immune and male reproductive systems as well as disease pathogenesis including tumorigenesis. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Transmembrane-4 superfamily includes several types of proteins possessing the four transmembrane-helix structure, such as the classical transmembrane-4 superfamily (tetraspanin) and MARVEL domain-containing proteins. Association with specialized membrane microdomains has been reported for MARVEL domain-containing proteins. 18 They participate in a variety of cellular processes including tumorigenesis. Promoter methylation of MAL, a putative tumorsuppressor gene (TSG), contributes to gastric and colon carcinogenesis. 19, 20 Loss of occludin leads to the progression of breast cancer. 21 Our previous study also showed that CMTM3 and CMTM5 possess tumor-suppressive functions with frequent epigenetic inactivation by promoter CpG methylation. 9, 10 CMTM6, CMTM7 and CMTM8 form a small gene cluster on chromosome 3p22. Loss of heterozygosity (LOH) of 3p, especially 3p12-22, is common in many cancer types including esophageal squamous cell carcinoma (ESCC), nasopharyngeal carcinoma (NPC) and lung carcinoma, suggesting the presence of critical TSGs. Several 3p TSGs have been identified, including RASSF1A (3p21.3), DLEC1 (3p22.3), HYA22 (3p22.3), LIMD1 (3p21.3), BLU/ZMYND10 (3p21.3), FHIT (3p14.2) and PLCD1 (3p22.3). [22] [23] [24] [25] [26] [27] [28] TSGs exert tumorsuppressive functions through inhibiting cell proliferation and migration, inducing cell apoptosis and cell cycle arrest. TSGs can be inactivated by both genetic and epigenetic mechanisms. Genetic deletion and point mutations disrupt TSG functions, whereas epigenetic mechanisms including promoter CpG methylation and histone modifications, lead to TSG silencing and functional loss thus also frequently involved in tumor development and progression. 29, 30 In this study, we investigated the expression, function and mechanism of a potential TSG-CMTM7, located at 3p22. 3 . We found that CMTM7 is broadly expressed in normal tissues but frequently silenced or downregulated in some carcinoma types. Promoter methylation and LOH were both found to be mechanisms contributing to CMTM7 downregulation. Ectopic CMTM7 expression led to the inhibition of cell proliferation and motility, through inducing G1/S cell cycle arrest by upregulating p27 and downregulating cyclin-dependent kinase 2 (CDK2) and 6 (CDK6). CMTM7 also promoted epidermal growth factor receptor (EGFR) internalization and further downregulated pAkt. Thus, CMTM7 acts as a novel functional TSG.
RESULTS
Only CMTM7 is frequently silenced by promoter methylation in some carcinoma types CMTM6, CMTM7 and CMTM8 form a gene cluster on 3p22, a chromosomal region rich in TSGs (Figure 1a) . We examined their expression profiles in a panel of normal adult tissues and tumor cell lines. Semiquantitative reverse transcription (RT)-PCR showed that CMTM6, CMTM7 and CMTM8 were all widely expressed in normal tissues (Figure 1b; Supplementary Figure 1) . However, CMTM7 was downregulated or silenced in multiple carcinoma cell lines, including 8 of 18 esophageal (44.4%), 3 of 6 nasopharyngeal (50%), 1 hypopharyngeal, 5 of 9 breast (55.5%), 2 of 4 cervical (50%), 1 of 16 gastric (6.25%) carcinoma cell lines and 1 of 3 glioma cell lines (33%; Figure 1c, Supplementary Figure 2B ). In contrast, no silencing of CMTM6 was detected in any cell line, whereas CMTM8 is expressed in most cell lines, except for its silencing in several lymphoma cell lines as well as occasional carcinoma cell lines (Supplementary Figure 1) .
The putative CMTM7 promoter identified by bioinformatics promoter analysis (http://www.genomatix.de) contains a typical CpG island, with common control elements-TATA and CAAT boxes (Figure 1a) . We thus analyzed CMTM7 promoter methylation by methylation-specific PCR (MSP). The specificity of our MSP system was validated using DNA not bisulfite treated (Supplementary Figure 2A) . Frequent methylation of CMTM7 promoter was observed in ESCC and NPC cell lines with reduced or silenced Figure 2B ). We also noted that no methylation was detected in several cell lines including KYSE180, in which CMTM7 was barely detectable (Figure 1c, Supplementary Figure 2B ), suggesting that other genetic alterations or histone modification may also account for CMTM7 downregulation.
To further assess a link between CMTM7 methylation and its silencing, we treated several silenced cell lines with a methyltransferase inhibitor Aza (A), alone or combined with a histone deacetylase inhibitor trichostatin A (T). The demethylation of the promoter restored CMTM7 expression (Figure 1d) . Bisulfite genomic sequencing analysis further confirmed that CMTM7 promoter was heavily methylated in tumor cell lines, but demethylated to varying degrees after pharmacological treatment (Figure 1e) .
We also performed multiplex differential genomic DNA PCR to investigate whether CMTM7 silencing/reduction is resulted from genetic deletion. Results revealed that no homozygous deletion was detected in any silenced or downregulated tumor cell lines with or without methylation, as well as in expressing normal epithelial cells and tissues (Supplementary Figure 3) . Thus, epigenetic silencing is the major mechanism for CMTM7 silencing in these cell lines, although possible hemizygous deletions still cannot be excluded.
CMTM7 is downregulated in primary tumors
We next evaluated CMTM7 expression in primary esophageal tumor tissues and their paired surgical margins. CMTM7 was downregulated in 20 of 22 (90%) tumor tissues by real-time PCR and semi-RT-PCR, but readily expressed in paired surgical margins (Figures 2a and d) . We further analyzed CMTM7 protein expression in representative samples by western blot and immunohistochemistry. Consistent with the mRNA expression, CMTM7 was downregulated in the protein level in ESCC tumor tissues but not in surgical margins (Figures 2b and c) .
Bioinformatics analysis with GeneCards database (http://bioinfo. weizmann.ac.il/cards) indicates that CMTM7 is downregulated in cervix, testis, lung, thymus and lymph node tumors compared with normal tissues. We thus further analyzed CMTM7 expression in large-scale tissues using tissue microarrays, immunohistochemistry results indicated that CMTM7 was also significantly downregulated or absent in esophageal, gastric, lung, cervix, pancreatic and liver tumor tissues (Table 1 Table 1) . Detailed bisulfite genomic sequencing methylation analyses of individual CpG sites of the CMTM7 promoter in two-paired esophageal tissues confirmed that CMTM7 was heavily methylated in primary tumors but rare in paired surgical margins (Figure 2f ).
Chromosome 3p allelic losses are frequently present in many types of cancers including esophageal carcinoma. Thus, two microsatellite markers, D3S2432 and D3S4525 located flanking CMTM7, were selected to assess genetic alterations within CMTM7 locus 3p22.3. A panel of 31 paired primary esophageal tumors was analyzed and 45% esophageal tumor tissues were observed LOH (Figure 2g ), suggesting that genetic alteration is also involved in CMTM7 disruption in tumor tissues.
CMTM7 exerts tumor-suppressive functions
The above expression and methylation results of CMTM7 indicate that it is a potential TSG. To determine if CMTM7 has tumorsuppressive ability, we first analyzed the subcellular localization of CMTM7 in HeLa cells. Overexpressed CMTM7 is located both on the cell membrane and in the cytoplasm, and shows a speckled distribution pattern across the cytoplasm with partial colocalization to the Golgi-system (Supplementary Figure 5A) . To confirm the in vivo tumor-suppressive ability of CMTM7, tumor formation in nude mice was performed by injecting KYSE180 cells infected with CMTM7 adenovirus or vector control. Within 5 weeks, solid tumors were readily visible in the control group, but only observed in one of three mice injected by CMTM7-expressing cells. In addition, the size and weight of tumors caused by CMTM7-expressing cells was significantly smaller than the control (**Po0.01; Figure 3e ). These data showed that CMTM7 indeed had tumor-suppressive ability in ESCC.
CMTM7 induces G1-S cell cycle arrest To elucidate the molecular mechanisms underlying the tumor cell growth inhibition by CMTM7, cell cycle status was studied by flow cytometry. When CMTM7 was expressed in KYSE410 and KYSE180 cell lines, there were significant increases of G1 phase cells (*Po0.05), but no effect was observed for CMTM7-expressing Het-1A and HEK293 cells (Figure 4a, Supplementary Figure 6D) . These results suggest expression of CMTM7 could induce G1-S cell cycle arrest. We further examined several key cell cycle regulators by western blot and real-time PCR. Results showed that p27 expression was upregulated, whereas CDK2 and CDK6 were downregulated in CMTM7-expressing KYSE180 cells compared with control (Figures 4b and c) , consistent with features of G1 cell cycle arrest.
CMTM7 promotes EGFR internalization and further downregulates pAkt Overexpression of EGFR has been reported in a number of human cancers, including ESCC. As ectopic CMTM7 expression could inhibit EGF-induced cell migration (Figure 3c ), we analyzed surface and intra-cellular EGFR in KYSE180 cells by flow cytometry. As shown in Figure 5a , cells transfected with CMTM7 (pink) contained less surface and more intra-cellular EGFR at steady state than control cells (green). Furthermore, we used indirect immunofluorescence to observe the localization of EGFR (Figure 5b) . At steady state, EGFR was mainly localized on the plasma membrane in control cells. However, in CMTM7-expressing cells, EGFR was internalized into cells, similar to flow cytometry results. These CMTM7 as a tumor suppressor methylated in carcinomas H Li et al phosphorylated Akt was downregulated, whereas no change in ERK activation was observed. These results suggested that the PI3K/Akt pathway is the EGFR downstream target inhibited by CMTM7.
DISCUSSION
CMTM is a novel family of proteins linking chemokines and transmembrane-4 superfamily, having important roles in the immune and male reproductive systems as well as tumorigenesis. Our previous studies indicate that CMTM3 and CMTM5 exert tumor-suppressive functions with frequent epigenetic inactivation by promoter CpG methylation. 9,10 CMTM6, CMTM7 and CMTM8 form a gene cluster on 3p22.3, an important TSG locus associated with the pathogenesis of multiple tumors. In this study, we found that CMTM7 is broadly expressed in human normal tissues and normal epithelial cell lines, while silenced or downregulated in some carcinoma cell lines and primary tumors because of promoter methylation and LOH. In primary tumors, the presence of various infiltrating normal tissue cells would also result in detectable expression of CMTM7 found in some cases. Moreover, other epigenetic alterations such as histone modifications would also likely contribute to CMTM7 downregulation in tumor cells.
The tumor-suppressive function of CMTM7 was investigated in vitro and in vivo. Ectopic expression of CMTM7 effectively suppresses esophageal carcinoma cell growth, motility and tumor formation in nude mice, but with no effect in immortalized normal cells, suggesting a tumor-specific suppression of CMTM7. CMTM7 is also able to inhibit G1-S phase transition through upregulating p27 and downregulating CDK2 and CDK6. G1-S phase transition is known to be a major checkpoint for cell cycle progression. Cyclindependent kinase inhibitors, serving as critical negative mediators during this transition through CDK inhibition, regulate the activity of cyclin E-CDK2 and cyclin D-CDK4/6 complex, resulting in Rb phosphorylation and Rb-E2F binding destruction. The released E2F activates the transcription of genes necessary for S-phase entry and cell cycle progression. 31 It is thus reasonable to speculate that CMTM7 is able to induce p27 expression, in turn, resulting in inhibition of CDK2 and CDK6 activity, and thus inhibit G1-S phase transition.
Expression of EGFR is common in various normal cells including cells of epidermal, mesenchymal and neurogenic origins. When CMTM7 as a tumor suppressor methylated in carcinomas H Li et al EGF binds to EGFR, signaling pathways are activated; this can lead to cell proliferation and differentiation. EGFR has an important role in cell differentiation, development, proliferation and maintenance. With EGFR overexpression because of mutation or structural alteration, carcinogenesis, invasion and metastasis are facilitated. 32 MARVEL domain protein families may be part of the machinery of membrane apposition events, such as transport vesicle biogenesis, neurotransmitter secretion and polarized membrane trafficking. CD82/KAI1, a metastasis tumor suppressor and a classical tetraspanin with one internalization consensus sequence YXXF in its cytosotic loop domain, is associated with EGFR and regulates EGFR internalization in several different types of epithelial cells. 33 The tyrosine-based YXXF motif can bind directly to the adaptor protein 2 m 2 -subunit. The adaptor protein 2 associates with clathrin and is involved in budding from the plasma membrane. 34 In CMTM family, CMTM8 contains two YXXF motifs and may be an attenuator of EGF-induced signaling via facilitating EGFR endocytosis and subsequent desensitization.
35
CMTM7 also contains one YXXF motif. In this study, we found that overexpressed CMTM7 is partially colocalized with the Golgisystem and promotes EGFR internalization at steady state. Ras/Raf/ mitogen-activated protein kinase kinase (MEK)/ERK and PI3K/Akt pathways are two important downstream signaling pathways of EGFR. 36 The PI3K/Akt pathway is linked to cell cycle regulation and frequently activated in many tumors. 37 In G1-S transition, activated PI3K/Akt signaling inhibits p27 activity. 38 Our studies indicated that CMTM7 inhibits phosphorylation of Akt, but has no effect on ERK. Thus, CMTM7 is associated with the inhibition of EGFR-PI3K/Akt signaling pathway, resulting in the upregulation of p27 and further inhibition of CDK2 and CDK6. CMTM7 may inhibit cell proliferation and migration via the EGFR-PI3K/Akt pathway.
Miyazaki et al. also reported that CMTM7 binds to BLNK in mouse B lymphoma Bal17 cells and negatively regulates BCR endocytosis through activation of ERK and c-Jun N-terminal kinase. 39 BLNK functions as a tumor suppressor in pre-B-cell leukemia, which can upregulate p27 and induce cell cycle arrest and apoptosis. 40 Our preliminary results show that BLNK is downregulated in esophageal carcinoma tissues compared with non-tumorous tissues. Endogenous CMTM7 is partially localized with BLNK in A549 cells, indicating that BLNK may also interact with human CMTM7 in non-leukemia cell line (data not shown). Further studies are needed to assess the direct interaction between CMTM7 and BLNK, and whether CMTM7 and BLNK have synergistic effect on the upregulation of p27.
Our preliminary studies also showed that CMTM6 and CMTM8 are downregulated in some esophageal tumors at the mRNA and protein levels (data not shown). It has been reported that CMTM6 is one of candidate deleted genes in lung adenocarcinoma with bronchioloalveolar carcinoma features, 41 although CMTM6 expression remained high in most cell lines examined except for some marginal downregulation in few cell lines. In HeLa cells, overexpression of CMTM6 has no effect on cell proliferation (Supplementary Figure 6) , indicating that CMTM6 may not possess tumor-suppressive functions, which needs further studies. For CMTM8, it can induce cell apoptosis through a mitochondriamediated pathway and function as a negative regulator of 4, 14, 35 CMTM8 is also downregulated in some cell lines. Future studies of roles of these genes in human diseases are needed.
CMTM is a novel family of proteins, with very limited studies conducted thus far for their molecular functions. In this study, we provided first evidences that CMTM7 is a potent TSG and has important suppressive role in cancer development and progression. A better understanding of the tumor-suppressive role of CMTM7 will significantly improve our knowledge about the roles of CMTM family proteins in carcinogenesis, and may lead to more effective management of cancers with CMTM7 alterations.
MATERIALS AND METHODS

Cell lines, treatment and tumor samples
Tumor cell lines studied include esophageal, nasopharyngeal, hypopharyngeal, gastric, hepatocellular, pancreatic, colorectal, breast, cervical, lung, prostate, bladder and renal carcinomas as well as glioma and lymphomas, with immortalized, non-transformed normal epithelia cell lines used as controls. 9, 31, 32 These cell lines were obtained either from the American Type Culture Collection (ATCC, Manassas, VA, USA) or our collaborators. All esophageal and NPC cell lines used in this study were of squamous cell type, 42 with only one NPC cell line C666-1 is Epstein-Barr virus-positive. 43 Some cell lines were treated with 10 mM of 5-aza-2'-deoxycytidine (Aza) (Sigma-Aldrich, St Louis, MO, USA) for 3 days, with or without further treatment with 100 nM trichostatin A (Cayman Chemical Co., Ann Arbor, MI, USA) for additional B16 h. Primary tumor tissues and paired non-tumor tissues were obtained from patients under primary surgery at the Peking University People's Hospital, with patients' consent and institutional ethics approval. Other archival normal and tumor DNA samples have been described. 9, 31 Tissue microarrays were purchased from Cybrdi Co. (Chaoying Biotechnology Co., Xi'an, China) and Outdo Biotechnology Co. (Shanghai Outdo Biotech Co., Shanghai, China).
Semiquantitative RT-PCR and real-time PCR analysis
Human multiple tissue RNA samples were purchased from Clontech (Mountain View, CA, USA) or Stratagene (La Jolla, CA, USA). Reverse transcription using random hexamer and RT-PCR using Go-Taq (Promega, Madison, WI, USA) were performed with primers for CMTM7, CMTM6 and CMTM8 (Supplementary Table 2 ). Detection of control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in all the studied samples has been confirmed before. 44, 45 Real-time PCR for p27 and CMTM7 were done as previously described, 9 according to the dissolving curve and electrophoresis, the samples with unspecific amplification were regarded as zero. For CDK2 and CDK6, we used Universal Probelibrary-based assays for quantitative RT-PCR. Quantitative PCR was run on ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The reactions were performed with TaqMan Gene Expression Master Mix, 200 nM primers and 100 nM probe. Amplification conditions were 10-min initial denaturation at 95 
Immunohistochemistry
Human tissue slides were deparaffinized and rehydrated. Antigen retrieval was done by heating a solution in 0.01 M citrate buffer (pH 6.0) twice for 5 min. The tissue chips were incubated with 3% (v/v) H 2 O 2 at room temperature for 10 min, rinsed twice and blocked in 10% normal goat serum for 30 min. The slides were then incubated at 37 o C for 1 h with anti-CMTM7 monoclonal antibody. Mouse monoclonal antibody against CMTM7 was prepared and purified in our laboratory. 33 After thorough washing, Dakocytomation Envision System HRP (DakoCytomation, Carpinteria, CA, USA) was applied for 30 min. After rinsing in phosphatebuffered saline, all slides were visualized with 0.05% (w/v) 3,3'-diaminobenzidine, and then counter-stained with hematoxylin. Mouse immunoglobulin G was used as a negative control.
The immunoreactive score of Remmele and Stegner (IRS) 48 was calculated according to immunostaining intensity (none ¼ 0; weak ¼ 1; moderate ¼ 2; strong ¼ 3) and percentage of positive tumor cells (none ¼ 0; o10% ¼ 1; 10-50% ¼ 2; 51-80% ¼ 3; 480% ¼ 4). For final statistical analysis, the IRS value of 0 was ranked as 0 (negative), the IRS values of 1-3 as 1 (weak expression), the IRS values of 4-8 as 2 (moderate expression) and the IRS values of 9-12 as 3 (strong expression).
Cell infection
Cells were infected with CMTM7 adenovirus (ad-CMTM7) or vectorcontaining adenovirus (ad-mock) as described. 11 Multiplicity of infection of 100, 200 and 400 were used, and the efficiency of infection was monitored by ad-pEGFP. Cells with 490% infection efficiency were used for further analysis.
Cell proliferation assay 
Cell migration assay
The migration assay was performed in a 48-well chemotaxis chamber (Neuro Probe, Cabin John, MD, USA) as previously described. 10 The top and bottom compartments of the chambers were separated by polycarbonate filters (8 mm pore size) coated with rat tail collagen I (BD Biosciences, San Jose, CA, USA). Briefly, serum-starved cells (1 Â 10 6 cells/ml) were resuspended in serum-free RPMI 1640 containing 0.1% bovine serum albumin and added to the upper well of the chamber. 20 ng/ml human EGF (Peprotech, Rockville, NJ, USA) was added to the lower wells. The cells were incubated for 7 h (KYSE410 and KYSE180) at 37 o C in a 5% CO 2 humidified atmosphere. After incubation, nonmigrated cells were scraped off and migrated cells were identified through fixing and staining. At least five random fields of vision per well were counted for quantitation of migrated cells. Triplicate wells were performed in each assay, and the assay was repeated at least three times.
Wound-healing assay Cells infected with CMTM7 or vector control were cultured until confluent; the cell layers were then carefully scratched using sterile tips.
9,45 After incubation for 24 or 36 h, the cells were photographed under a phase contrast microscope.
Cell cycle analysis
Cells infected with CMTM7 or vector control were harvested and fixed in 70% ethanol and stained with propidium iodide, and DNA content was analyzed by FACSCalibur (BD Biosciences). The results were analyzed by ModFit software (Verity Software House, Topsham, ME, USA).
Tumor formation in nude mice
In vivo tumor-suppressive ability of CMTM7 was investigated by tumor xenograft experiment. In all, 4 Â 10 6 KYSE180 cells infected with CMTM7 or vector control were injected subcutaneously into the left dorsal flank of 3 or 4 nude mice (4-6 weeks old), respectively. Tumor formation in nude mice was monitored over a 5-week period. The tumor volume was calculated by the formula V ¼ 0.5 Â L Â W 2 .
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Flow cytometry
Cells infected with CMTM7 or vector control were harvested and washed with phosphate-buffered saline, fixed in 4% paraformaldehyde and/or permeabilized in 0.1% Triton-X-100, then blocked and incubated with anti-EGFR antibody and fluorescein isothiocyanate-conjugated secondary antibody. Cells were counted by flow cytometry (FACS Calibur) with an excitation of 488 nm and analyzed with CELLQuest software (BD Biosciences).
Immunofluorescence
Cells infected with CMTM7 or vector control were harvested and fixed with 4% paraformaldehyde, permeabilized in 0.1% Triton-X-100, and blocked with 3% fetal bovine serum. The cells were then treated with anti-EGFR antibody for 1 h and incubated with fluorescein isothiocyanate-conjugated secondary antibody for 1 h. This experiment was replicated three times. Cells were imaged with Leica TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany).
Western blot analysis
Western blot was done according to the standard protocol as described previously. 9 Signals were detected by Odyssey Infrared Imager (LICOR Bioscience, Lincoln, NE, USA).
Antibodies used were: EGFR, p53, p27, p21, CDK2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), cyclin D1 (NeoMarkers, Fremont, CA, USA), cyclin E1 (Bioworld Technology, Inc., St Louis Park, MN, USA), CDK4, CDK6, phospho-Akt
Ser473
, total-Akt and total-ERK (Cell Signaling, Beverly, MA, USA), phospho-ERK Thr202/Tyr204 (KangChen Bio-Tech, KangChen, Shanghai, China), b-actin (Sigma-Aldrich) and IRDye secondary antibodies against mouse or rabbit immunoglobulin G (Li-Cor Biosciences). The anti-CMTM7 mouse monoclonal antibody and anti-CMTM6 rabbit polyclonal antibody were made in our lab.
Statistical analysis
Statistical analysis was carried out using Statistical Package for Social Sciences 14.0 for Windows (SPSS Inc., Chicago, IL, USA). Student's t-test was used to analyze the results expressed as mean±s.d. Differences were considered significant when Po0.05.
